Abbas Hussain insider trades: Moderna (MRNA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Abbas reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | MRNA | ↓ Sell | 5,682 | $46.63 | $265K | Direct | May 4, 2026 (3d) |
| Dec 9, 2025 | MRNA | ↓ Sell | 504 | $27.60 | $14K | Direct | Dec 11, 2025 (2d) |
| Jun 11, 2025 | MRNA | ↓ Sell | 312 | $28.00 | $9K | Direct | Jun 12, 2025 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other MRNA insiders
Open-market trades in the last 12 months
About Abbas Hussain's insider trades
Abbas Hussain is a director at Moderna (MRNA). Since Jun 11, 2025, Abbas has reported no open-market purchases and 3 sales worth $288K on SEC Form 4. In the last 12 months: 2 sales ($279K).
Their filings also include grants and awards (7 filings), option exercises (5 filings), shares withheld for taxes (2 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MRNA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.